脂蛋白a与冠状动脉慢血流现象的关系
Relationship between Lipoprotein a and Coronary Slow Flow Phenomenon
DOI: 10.12677/ACM.2023.132286, PDF,   
作者: 高 亮*, 邵 琦, 王有志：青岛大学，山东 青岛；尹 磊#：青岛大学附属医院，山东 青岛
关键词: 冠状动脉慢血流现象；CSFP脂蛋白a Lp(a)；Coronary Slow Flow Phenomenon； CSFP Lipoprotein a Lp(a)
摘要: 目的：众多研究已证实脂蛋白a[Lp(a)]是冠心病的重要风险因素，冠状动脉慢血流现象(coronary slow flow phenomenon, CSFP)是一个真实存在的血管造影现象，目前两者之间关系尚不清楚。因此我们旨在研究Lp(a)和CSFP之间的关系。方法：选取我院2019年7月~2022年7月因疑似冠状动脉疾病接受冠状动脉造影检查发现CSFP的患者120例作为CSFP组，随机选取120例冠脉血流正常患者作为Non-CSFP组。比较两组患者临床资料及相关实验室检查指标。结论：Lp(a)是CSFP独立风险因素，其浓度随着涉及血管数量的增加而增加，Lp(a)可以预测CSFP的发生和严重程度。
Abstract: Objective: Many studies have confirmed that lipoprotein a is an important risk factor of coronary heart disease, and coronary slow flow phenomenon (CSFP) is a real angiography phenomenon. At present, the relationship between the two remains unclear. Therefore, we aim to study the rela-tionship between Lp(a) and CSFP. Methods: A total of 120 patients with CSFP detected by coronary angiography in our hospital from July 2019 to July 2022 due to suspected coronary artery disease were selected as the CSFP group, and 120 patients with normal coronary blood flow were randomly selected as the Non-CSFP group. The clinical data and related laboratory test indexes were com-pared between the two groups. Conclusion: Lp(a) is an independent risk factor for CSFP, and its concentration increases with the number of involved vessels. Lp(a) can predict the occurrence and severity of CSFP.
文章引用：高亮, 邵琦, 王有志, 尹磊. 脂蛋白a与冠状动脉慢血流现象的关系[J]. 临床医学进展, 2023, 13(2): 2052-2058. https://doi.org/10.12677/ACM.2023.132286

参考文献

[1] Tambe, A.A., et al. (1972) Angina Pectoris and Slow Flow Velocity of Dye in Coronary Arteries—A New Angiograph-ic Finding. American Heart Journal, 84, 66-71. [Google Scholar] [CrossRef] [PubMed]
[2] Saadat, M., et al. (2019) Discrimination between Obstructive Coronary Artery Disease and Cardiac Syndrome X in Women with Typi-cal Angina and Positive Exercise Test; Utility of Cardiovascular Risk Calculators. Medicina (Kaunas), 55, 12. [Google Scholar] [CrossRef] [PubMed]
[3] Cin, V.G., et al. (2003) Diffuse Intimal Thickening of Coronary Arteries in Slow Coronary Flow. Japanese Heart Journal, 44, 907-919. [Google Scholar] [CrossRef] [PubMed]
[4] Sezg1in, A.T., et al. (2003) Vascular Endothelial Function in Patients with Slow Coronary Flow. Coronary Artery Disease, 14, 155-161. [Google Scholar] [CrossRef] [PubMed]
[5] Zhang, X., Ding, J. and Xia, S. (2021) A Preliminary Study of MMP-9 and sCD40L in Patients with Coronary Slow Flow. Annals of Palliative Medicine, 10, 657-663. [Google Scholar] [CrossRef] [PubMed]
[6] Fragasso, G., et al. (2009) Coronary Slow-Flow Causing Transient Myocardial Hypoperfusion in Patients with Cardiac Syndrome X: Long-Term Clinical and Functional Prognosis. Inter-national Journal of Cardiology, 137, 137-144. [Google Scholar] [CrossRef] [PubMed]
[7] Carmena, R., Duriez, P. and Fruchart, J.C. (2004) Atherogenic Lipoprotein Particles in Atherosclerosis. Circulation, 109, III2-III7. [Google Scholar] [CrossRef] 
[8] Welsh, P., et al. (2022) Lipoprotein(a) and Cardiovas-cular Disease: Prediction, Attributable Risk Fraction, and Estimating Benefits from Novel Interventions. European Jour-nal of Preventive Cardiology, 28, 1991-2000. [Google Scholar] [CrossRef] [PubMed]
[9] Beltrame, J.F. (2012) Defining the Coronary Slow Flow Phenomenon. Circulation Journal, 76, 818-820. [Google Scholar] [CrossRef] 
[10] Yolcu, M., et al. (2020) New Indicator of Cellular Ischemia in Coro-nary Slow-Flow Phenomenon: Cell-Free DNA. Turk Kardiyoloji Dernegi Arsivi, 48, 558-565. [Google Scholar] [CrossRef] [PubMed]
[11] Ong, P., et al. (2018) International Standardization of Diagnostic Criteria for Microvascular Angina. International Journal of Cardiology, 250, 16-20. [Google Scholar] [CrossRef] [PubMed]
[12] Cakmak, H.A., et al. (2015) Relationship between Serum Visfatin Levels and Coronary Slow-Flow Phenomenon. Herz, 40, 921-928. [Google Scholar] [CrossRef] [PubMed]
[13] Aciksari, G., et al. (2021) The Relationship between Triglycer-ide/High-Density Lipoprotein Cholesterol Ratio and Coronary Slow-Flow Phenomenon. The International Journal of Cardiovascular Imaging, 38, 5-13. [Google Scholar] [CrossRef] 
[14] Kamstrup, P.R., et al. (2008) Pentanucleotide Repeat Polymor-phism, Lipoprotein(a) Levels, and Risk of Ischemic Heart Disease. The Journal of Clinical Endocrinology & Metabolism, 93, 3769-3776. [Google Scholar] [CrossRef] [PubMed]
[15] Willeit, P., et al. (2018) Baseline and On-Statin Treatment Lipoprotein(a) Levels for Prediction of Cardiovascular Events: Individual Patient-Data Meta-Analysis of Statin Outcome Trials. The Lancet, 392, 1311-1320. [Google Scholar] [CrossRef] 
[16] O’Donoghue, M.L., et al. (2019) Lipoprotein(a), PCSK9 In-hibition, and Cardiovascular Risk. Circulation, 139, 1483-1492. [Google Scholar] [CrossRef] 
[17] Zhu, L., et al. (2016) Plasma Lipoprotein(a) Levels Are Associated with the Severity of Coronaryheart Disease in Han Chinese People. Turkish Journal of Medical Sciences, 46, 1033-1041. [Google Scholar] [CrossRef] [PubMed]

为你推荐